Evaluation and construction of diagnostic criteria for inclusion body myositis

Objective: To use patient data to evaluate and construct diagnostic criteria for inclusion body myositis (IBM), a progressive disease of skeletal muscle. Methods: The literature was reviewed to identify all previously proposed IBM diagnostic criteria. These criteria were applied through medical records review to 200 patients diagnosed as having IBM and 171 patients diagnosed as having a muscle disease other than IBM by neuromuscular specialists at 2 institutions, and to a validating set of 66 additional patients with IBM from 2 other institutions. Machine learning techniques were used for unbiased construction of diagnostic criteria. Results: Twenty-four previously proposed IBM diagnostic categories were identified. Twelve categories all performed with high (≥97%) specificity but varied substantially in their sensitivities (11%–84%). The best performing category was European Neuromuscular Centre 2013 probable (sensitivity of 84%). Specialized pathologic features and newly introduced strength criteria (comparative knee extension/hip flexion strength) performed poorly. Unbiased data-directed analysis of 20 features in 371 patients resulted in construction of higher-performing data-derived diagnostic criteria (90% sensitivity and 96% specificity). Conclusions: Published expert consensus–derived IBM diagnostic categories have uniformly high specificity but wide-ranging sensitivities. High-performing IBM diagnostic category criteria can be developed directly from principled unbiased analysis of patient data. Classification of evidence: This study provides Class II evidence that published expert consensus–derived IBM diagnostic categories accurately distinguish IBM from other muscle disease with high specificity but wide-ranging sensitivities.

[1]  H. Mitsumoto,et al.  Inclusion body myositis presenting as treatment-resistant polymyositis. , 1987, Arthritis and rheumatism.

[2]  Richard J. Barohn,et al.  Inclusion body myositis , 2000, Current treatment options in neurology.

[3]  J. Verschuuren,et al.  A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. , 2011, Brain : a journal of neurology.

[4]  M. Rose,et al.  International Workshop : Inclusion Body Myositis , 2 – 4 December 2011 , Naarden , The Netherlands , 2013 .

[5]  M. G. Hanna,et al.  Inclusion body myositis MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008 , 2010, Neuromuscular Disorders.

[6]  B. Katirji Diagnostic Criteria for Neuromuscular Disorders , 1994, Neurology.

[7]  David Hilton-Jones,et al.  International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009 , 2010, Neuromuscular Disorders.

[8]  M. Shuman,et al.  Retraction: Stricker RB, Abrams DI, Corash L, Shuman MA. Target platelet antigen in homosexual men with immune thrombocytopenia. N Engl J Med 1985; 313:1375-80. , 1991 .

[9]  F. Mastaglia,et al.  Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. , 2002, Rheumatic diseases clinics of North America.

[10]  F. Breedveld,et al.  Epidemiology of inclusion body myositis in the Netherlands: A nationwide study , 2000, Neurology.

[11]  F L Mastaglia,et al.  Sporadic inclusion body myositis: Phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[12]  Ivan Bratko,et al.  Microarray data mining with visual programming , 2005, Bioinform..

[13]  J. Holton,et al.  Polymyositis, Dermatomyositis, and Inclusion Body Myositis , 2013 .

[14]  M. Dalakas,et al.  Inclusion body myositis and myopathies , 1997, Journal of the Neurological Sciences.

[15]  David Hilton-Jones,et al.  Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  W J Litchy,et al.  Inclusion body myositis. Observations in 40 patients. , 1989, Brain : a journal of neurology.